Investment Director, Uniseed
| Role | Organisation | Sources |
|---|---|---|
| Hatchtech | GBS Ventures | |
| Investment Director | Uniseed | - |
Stories naming Dr John Kurek. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.